NCT06795412 2026-03-06
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology, Inc
Phase 1/2 Recruiting
Pyxis Oncology, Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Shandong Boan Biotechnology Co., Ltd
RemeGen Co., Ltd.